← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
daclatasvir, asunaprevir and beclabuvir
J05AP58
Forms & Strengths
- Daclatasvir 30mg, asunaprevir 200mg, beclabuvir 75mg fixed-dose combination tablets
Adult Dosing
- Take 2 tablets orally once daily with or without food for 12 weeks
- Dose adjustments may be necessary for patients with severe renal impairment or hepatic impairment
Pediatric Dosing
- Safety and efficacy not established in patients under 18 years of age
- Use in pediatric patients is not recommended due to limited data
Indications
- Treatment of chronic hepatitis C virus (HCV) genotype 1 infection
- Treatment of HCV genotype 1 infection in patients with compensated cirrhosis
Mechanism of Action
- Daclatasvir inhibits HCV NS5A protein, asunaprevir inhibits HCV NS3 protease, and beclabuvir inhibits HCV NS5B polymerase
- Triple mechanism of action targets multiple steps in the HCV replication cycle
Contraindications
- Hypersensitivity to daclatasvir, asunaprevir, or beclabuvir
- Co-administration with strong CYP3A4 inducers or certain other medications
Adverse Reactions
- Headache, fatigue, diarrhea, nausea, rash, and pruritus
- Elevations in alanine transaminase (ALT) and aspartate transaminase (AST) levels
Drug Interactions
- Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort) may decrease daclatasvir, asunaprevir, and beclabuvir concentrations
- Co-administration with certain anticonvulsants, antimycobacterials, and HIV protease inhibitors may require dose adjustments
Curated Content: Needs Vetting Before Put to Clinical Use